Abstract
Since neurosurgery followed by high dose radiation therapy invariably fails to completely remove malignant brain gliomas, these tumors appear to be excellent candidates for adjuvant chemotherapy of the residual disease. At least three parameters can be measured in brain tumor chemotherapeutic trials: (1) prolongation of survival, (2) rate and duration of objective remissions, and (3) prolongation of the disease-free interval (Table 1). As in other neoplasms, these parameters do not necessarily measure the same phenomenon and may give apparently contradictory results, especially when the drugs used are moderately active. Therefore, their results should be considered separately. The therapeutic effects on the residual tumor cells are tested in trials that measure the disease-free interval and/or total survival.
This work is supported by the NCI contract NO1-CM-53840.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Armentrout, S. A., Foltz, E., Vermund, H., Otis, P. T.: Comparison of postoperative irradiation alone and in combination with BCNU (NSC-409962) in management of malignant gliomas. Cancer Chemother. Rep. 58, 841–844 (1976).
Band, P. R., Weir, Urtasun, R. C., Blain, G., McLean, D., Wilson, F., Mielke, B., Grace, M.: Radiotherapy and CCNU in Grade III and IV astrocytoma. ASCO Abs. p. 161 (1974).
Brisman, R., Housepian, E. M., Chang, C., Duffy, P., Balis, E.: Adjuvant nitrosourea therapy for glioblastomas. Arch. Neurol. 33, 745–750 (1976).
Edland, R. W., Javid, M., Ansfield, J. F.: Glioblastoma multiforme. An analysis of the results of post-operative radiotherapy alone versus radiotherapy and concomitant 5-Fluorouracil. Am. J. Roentgenol. 3, 337–342 (1971).
EORTC Brain Tumor Group. Effects of CCNU on the survival, rate of objective remission and duration of free interval in patients with malignant brain glioma. First evaluation. Eur. J. Cancer 12, 41–45 (1976).
EORTC Brain Tumor Group. Effects of CCNU on the survival, rate of objective remission and duration of free interval in patients with malignant brain glioma. Final evaluation. Eur. J. Cancer (in press) (1978).
Reagan, T. J., Bisel, H. F., Childs, D. S., Layton, D. D., Rhoton, A. L. (Jr.), Taylor, W. F.: Controlled study of CCNU radiation therapy in malignant astrocytomas. J. Neurol. 44, 186–190 (1976).
Walker, M. D., Alexander, E. (Jr.), Hunt, W. E., Leventhal, C. M., Mahaley, M., Mealey, J. S. (Jr.), Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., Gehan, E. A.: Evaluation of mithramycin in the treatment of anaplastic gliomas. J. Neurol. 44, 655–667 (1976).
Walker, M. D., Gehan, E. A.: An evaluation of 1-3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) and irradiation alone and in combination for the treatment of malignant glioma. AACR Abs. p. 67 (1972).
Walker, M. D., Strike, T. A.: An evaluation of methyl-CCNU, BCNU and radiotherapy in treatment of malignant glioma. AACR Abs. p. 163 (1976).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Hildebrand, J. (1979). Adjuvant Chemotherapy in Malignant Brain Gliomas. In: Bonadonna, G., Mathé, G., Salmon, S.E. (eds) Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II. Recent Results in Cancer Research, vol 68. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81332-0_61
Download citation
DOI: https://doi.org/10.1007/978-3-642-81332-0_61
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81334-4
Online ISBN: 978-3-642-81332-0
eBook Packages: Springer Book Archive